Tag: CSE:RAMM

July 16, 2020

RAMM Pharma Announces Approval and Registration of Epifractán™ 2 Percent by Peru’s Ministry of Health

RAMM Pharma is pleased to announce that the Company’s Epifractán™ 2% formulation has been approved and registered by Peru’s Ministry...
July 9, 2020

RAMM Pharma Announces Approval and Registration of Epifractán™ 5 Percent by Peru’s Ministry of Health and Enters Distribution Agreement to Supply Pharmacies in Peru

RAMM Pharma Corp. is pleased to announce that the Company’s Epifractán™ 5% formulation has been approved and registered by Peru’s...
April 15, 2020

RAMM Pharma Corp. Announces Intention to Commence Normal Course Issuer Bid

RAMM Pharma Corp. (CSE:RAMM)announces its intention to commence a normal course issuer bid, under which it may purchase up to...
March 30, 2020

RAMM Pharma Corp. Announces Postponement of Filing of Interim Financial Statements

RAMM Pharma announces that it will not be filing its interim financial statements for the quarter ended January 31, 2020.
March 26, 2020

RAMM Pharma Corp. Receives Federal Approval and Registration of XALEX™ 10 (cannabidiol) Oral Solution

RAMM Pharma (CSE:RAMM)is pleased to announce that the Uruguayan Ministry of Public Health has approved and registered XALEX™ 10 (cannabidiol)...
March 23, 2020

RAMM Pharma Corp. Provides Details on Operational Activities to Support COVID-19 Medical Response Effort & Corporate Update

RAMM Pharma Corp. (CSE: RAMM) provided a corporate update and information regarding the Company’s ongoing support of the medical community’s...
February 25, 2020

RAMM Pharma Corp. to Acquire NettaLife, a Leading Developer of Cannabis-Based Products for Pets and Large Animals

RAMM Pharma Corp. has entered into a definitive agreement dated February 24, 2020 to acquire Glediser S.A. operating as NettaLife™